Evidence supporting the use of: Curcumin
For the health condition: Osteoporosis

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Curcumin, the primary active compound in turmeric (Curcuma longa), has been investigated for its potential role in supporting or treating osteoporosis. Osteoporosis is characterized by decreased bone mass and increased fracture risk. The scientific rationale for using curcumin in osteoporosis primarily revolves around its anti-inflammatory and antioxidant properties, as chronic inflammation and oxidative stress are known contributors to bone loss.

Several preclinical studies (in vitro and animal models) have demonstrated that curcumin can inhibit osteoclastogenesis (the formation of bone-resorbing cells), promote osteoblast differentiation (the formation of bone-building cells), and suppress inflammatory cytokines known to exacerbate bone loss. For example, animal studies have shown that curcumin supplementation can attenuate bone loss in ovariectomized rats, a common model for postmenopausal osteoporosis, likely through modulation of the RANK/RANKL/OPG pathway and reduction of oxidative damage.

However, high-quality human clinical trial data are lacking. Most evidence for curcumin’s benefit in osteoporosis is limited to laboratory and animal research, with only a few small-scale clinical studies, often with methodological limitations. Issues such as curcumin’s low bioavailability also complicate its translation to clinical use. Thus, while there is a scientific basis and some promising early data, robust human trials are needed before curcumin can be confidently recommended for osteoporosis management.

More about curcumin
More about Osteoporosis